Telmisartan in the treatment of hypertensive patients

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Podzolkov V.I.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russian Federation, Moscow? Russia

Tarzimanova A.I.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Telmisartan in the treatment of hypertensive patients

Authors:

Podzolkov V.I., Tarzimanova A.I.

More about the authors

Journal: Therapeutic Archive. 2017;89(6): 110‑113

DOI: 10.17116/terarkh2017896110-113

Read: 20905 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Podzolkov VI, Tarzimanova AI. Telmisartan in the treatment of hypertensive patients. Therapeutic Archive. 2017;89(6):110‑113. (In Russ.)
https://doi.org/10.17116/terarkh2017896110-113

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Study of the levocarnitine efficacy for the treatment of moderate cognitive impairment in patients with hypertension. Russian Journal of Preventive Medicine. 2025;(4):45-50

Angiotensin model as a new approach to study of mesenchymal stem cell senescence. Russian Cardiology Bulletin. 2025;(2):20-26

Visceral obesity is a reversible factor in pathogenesis of major cardiovascular diseases. Russian Cardiology Bulletin. 2025;(3):11-16

Features of the interpretation of bodily sensations by patients with arterial hypertension. Russian Journal of Preventive Medicine. 2025;(10):82-87

Study of the effectiveness of the drug Elcarnitine in the correction of increased variability of arterial pressure in patients with hypertensive disease and cognitive dysfunction. Russian Journal of Preventive Medicine. 2025;(10):88-92

Features of arterial hypertension in individuals with anxiety disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):44-51

Harmonic analysis of pelvic electrophysiological signals in cardiovascular diseases for non-invasive assessment of autonomic nervous system. Russian Cardiology Bulletin. 2025;(4-2):117-125

Abstract:

The paper highlights the use of telmisartan, one of the currently available angiotensin receptor blockers, for the treatment of patients with hypertension, metabolic syndrome, and those at high cardiovascular risk. Telmisartan treatment allows blood pressure control, provides organ protection at different stages of the cardiovascular continuum, and reduces the risk of cardiovascular diseases and death. The additional properties and pleiotropic activity of the drug determines its wide range of applications in cardiology.

Keywords:

telmisartan

hypertension

angiotensin receptor blockers

Authors:

Podzolkov V.I.

Sechenov First Moscow State Medical University of Healthcare Ministry of the Russian Federation, Moscow? Russia

Tarzimanova A.I.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Close metadata

References:

Podzolkov VI. Arterial hypertention. Moscow: Medical information Agency; 2016. (In Russ.)
Podzolkov VI, Tarzimanov AI. A new generation of blockers receptors of angiotensin. Moscow: Planida; 2013. (In Russ.)
Shalnova SA, Konradi AO, Karpov YuA, Kontsevaya AV, Deev AD, Kapustina AV, Khudyakov MB, Shlyakhto EV, Boytsov SA. Cardiovascular mortality in 12 Russian Federation regions — participants of the «Cardiovascular Disease epidemiology in Russian Regions» study. Russ J Cardiol. 2012;5(97):6-11. (In Russ.)
ESH-ESC Guidelines Committee. 2013 ESH-ESC guidelines for the management of arterial hypertension. J Hypertension. 2013;31:1281-1357. doi:10.1097/01.hjh.0000431740.32696.cc
Ram C. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121:656-663. doi:10.1016/j.amjmed.2008.02.038
Munger MA. Therapy with blockers of receptors of angiotensin and cardiovascular protection. Modern evidence base and development prospects. Cardiovascular therapy and prevention. 2011;10(7):93-104. (In Russ.)
Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-645.
Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens. 2002;16(Suppl.2): S13-S16. doi:10.1038/sj.jhh.1001391
Williams B, Gosse P, Lowe L, PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24:193-200.
Lacourcire Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19:104-112. doi:10.1016/j.amjhyper.2005.10.001
Gosse P, Neutel JM, Schumacher H et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit. 2007;12:141-147. doi:10.1097/MBP.0b013e3280b10bbd
Williams B, Lacourcire Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009;23(9):610-619. doi:10.1038/jhh.2009.4
The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183. doi:10.1016/S0140-6736(08)61242-8
The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. doi:10.1056/NEJMoa0801317
Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy — rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res. 2005;33:677-686. doi:10.1177/147323000503300610
Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy — rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res. 2005;33:677-686. doi:10.1177/147323000503300610
Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008; 23(10):3174-3183. doi:10.1093/ndt/gfn230
Bichu P, Nistala R, Khan A et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag. 2009;5:129-140.
Sharma AM, Hollander A, Koster J; on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clinical Nephrology. 2005;63(4):250-257.
Ratova LG, Chazova IE. the Effect of antihypertensive therapy micardis plus on renal function (clinical sample). System hypertension. 2010;2:66-70. (In Russ.)
Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378(9785):31-40. doi:10.1016/S0140-6736(11)60679-X
Francisco A Monsalve, Radha D Pyarasani, Fernando Delgado-Lopez, Rodrigo Moore-Carrasco. Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases. Mediators Inflamm. 2013:549-627. doi:10.1155/2013/549627
Usuda D, Kanda T. Peroxisome proliferator-activated receptors for hypertension. World J Cardiol. 2014;6(8):744-754. doi:10.4330/wjc.v6.i8.744
Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010;6(5):657-691. doi:10.2217/fca.10.86
Cheang WS, Tian XY, Wong WT, Huang Y. The peroxisome proliferator — activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol. 2015;172(23):5512-5522. doi:10.1111/bph.13029

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.